## Company Profile UPS Japan Co., Ltd. — the Japanese subsidiary of United Parcel Service (UPS). Operates integrated express parcel, air and ocean freight forwarding, customs brokerage, warehousing and supply‑chain solutions across Japan. UPS Japan is a full‑service logistics provider with dedicated healthcare/cold‑chain offerings (temperature‑controlled transport and warehousing, GDP/GMP compliance support), serving exporters and importers of high‑value goods (electronics, medtech, pharmaceuticals) on major Japan–US and Japan–Europe corridors. As part of the global UPS network it handles cross‑border documentation, customs clearance and time‑sensitive air freight for corporate and SME shippers. ## Pain Points 1) Customers face immediate capacity and schedule volatility for Japan‑origin air and ocean lanes (Q2‑2026 belly capacity contraction; blank sailings on Transpacific) — this creates urgent rebooking, routing and premium pricing needs for time‑/temperature‑sensitive exports. 2) Exporters of medtech, biologics and clinical trial materials are struggling with GDP/GMP compliance, limited temperature‑controlled storage near gateways and risk of temperature excursions — increasing claims and potential write‑offs. 3) High administrative burden: 8–12 documents per shipment, complex RoO/FTA certification and Japanese regulatory/documentation requirements (PMD Act) cause delays and rework that reduce shipper throughput and create friction for scaling exports. ## Intel Summary === MULTI-DIMENSION RESEARCH === === 1. [MARKET EVENTS] Japan air and ocean freight market – 2026 Asia–US–Europe lane capacity and rate trends === **Overall air cargo environment, with focus on Japan/Asia origins** - IATA’s Q1‑2026 Air Transport Chartbook shows **Asia–Europe traffic (RPK)** growing solidly, while scheduled seat capacity out of several Asia-Pacific origins, **including Japan**, is expected to **contract in Q2‑2026**, indicating tighter bellyhold capacity even as demand rises.([iata.org](https://www.iata.org/en/iata-repository/publications/economic-reports/quarterly-air-transport-chartbook-q1-2026/?utm_source=openai)) - IATA notes wide divergence across Asia-Pacific departures; Japan is explicitly listed among markets where **scheduled capacity will shrink**, while others expand, implying relatively more constrained lift for Japan-origin long‑haul air freight vs. some regional peers.([iata.org](https://www.iata.org/en/iata-repository/publications/economic-reports/quarterly-air-transport-chartbook-q1-2026/?utm_source=openai)) - A February 2026 airfreight market commentary (Metro Global) reports **global air cargo volumes up ~5% YoY** in the second and third weeks of January 2026, with **Asia Pacific → Europe volumes up close to 20% YoY** and **Asia → US volumes up ~6% YoY**. Capacity behaviour (airline deployments, freighter additions and withdrawals) is described as the dominant driver of rate dynamics.([metro.global](https://metro.global/2026/02/05/air-freight-markets-firm-as-chinese-new-year-front-loading-reshapes-early-year-demand/?utm_source=openai)) **Rate and balance conditions – structurally loose but lane‑specific tightening** - A UPS Supply Chain “2026 Supply Chain Outlook” for Japan and global markets states that **air freight capacity is expected to keep growing faster than demand in 2026**, creating **structural oversupply in several regions** and pressuring yields overall. Global airline cargo profits are projected to swing from roughly **USD 60 bn in 2024** to **USD 20 bn in 2025**, and a **USD 10 bn loss in 2026** under current rate/utilisation assumptions, illustrating downwards rate pressure.([ups.com](https://www.ups.com/jp/en/supplychain/resources/news-and-market-updates/2026-supply-chain-outlook?utm_source=openai)) - However, for **Asia–US and Asia–Europe** lanes, multiple sources point to pockets of tightening: - Metro Global notes strong January 2026 demand ex‑Asia Pacific and indicates carriers are using capacity discipline to keep rates from collapsing.([metro.global](https://metro.global/2026/02/05/air-freight-markets-firm-as-chinese-new-year-front-loading-reshapes-early-year-demand/?utm_source=openai)) - For Japan specifically, IATA’s forecast of **contracting scheduled capacity out of Japan in Q2‑2026** implies higher load factors and more resilient rates on outbound Japan lanes versus broader Asia where capacity is still expanding.([iata.org](https://www.iata.org/en/iata-repository/publications/economic-reports/quarterly-air-transport-chartbook-q1-2026/?utm_source=openai)) **Ocean freight: Transpacific (Asia–US) and Asia–Europe dynamics that affect Japan** - A February 2026 freight market update (JM Rodgers) reports: - **Transpacific spot rates near or below carrier break‑even**, particularly on Asia–US West Coast, leading carriers to intensify **blank sailings** as a capacity management tool. - In **February 2026 alone, over 100 voyages were cancelled** on the Transpacific to stabilize rates.([jmrodgers.com](https://www.jmrodgers.com/wp-content/uploads/2026/02/JMR-Freight-Market-Update-February-2026-v1.0.pdf?utm_source=openai)) - Japan‑related services (e.g., key alliances’ loops calling Yokohama, Tokyo, Kobe, Nagoya) are part of these wider Transpacific network adjustments; blank sailings typically hit North Asia strings disproportionately. - A Freightos/Baltic Daily Index excerpt (April 7, 2026) shows: - **Asia–US West Coast spot prices up 11% WoW**, and **Asia–US East Coast up 5%** that week, with Asia–US West Coast rates climbing about **40% vs pre‑war levels to roughly USD 2,400/FEU**, despite still‑weak demand. - Asia–Europe rates are up roughly **30% YoY**, helped by war‑related disruptions, fuel costs and selected blank sailings.([reddit.com](https://www.reddit.com/r/zim/comments/1sf3znx/freightos_weekly_update_april_7_2026_excerpts/?utm_source=openai)) - Drewry’s May 21, 2026 World Container Index commentary shows the **composite WCI up 6% WoW to USD 2,712/FEU**, mainly on higher Asia–Europe rates; carriers have announced **seven new planned blank sailings on Transpacific next week**, indicating ongoing attempts to tighten capacity.([reddit.com](https://www.reddit.com/r/zim/comments/1tjtnx6/drewry_world_container_index_excerpts_rally_in/?utm_source=openai)) **Implications specifically for Japan–US–Europe flows in 2026** - **Japan–US (air):** - Belly capacity on Japan–US passenger routes is constrained relative to 2019 due to IATA‑flagged capacity contraction from Japan in Q2‑2026.([iata.org](https://www.iata.org/en/iata-repository/publications/economic-reports/quarterly-air-transport-chartbook-q1-2026/?utm_source=openai)) - Structural global oversupply plus moderate Asia–US volume growth (~6% YoY) means **rates are off the 2021–22 peaks but remain volatile**, particularly around front‑loading before Golden Week and peak seasons.([metro.global](https://metro.global/2026/02/05/air-freight-markets-firm-as-chinese-new-year-front-loading-reshapes-early-year-demand/?utm_source=openai)) - **Japan–Europe (air):** - Strong **Asia Pacific → Europe cargo growth (~20% YoY)** in early 2026 lifts demand; with Japan capacity constrained, **spot export rates from major Japanese gateways (NRT, HND, KIX)** to Europe are expected to be firm to slightly rising vs 2025 averages, especially for priority and temperature‑controlled cargo.([metro.global](https://metro.global/2026/02/05/air-freight-markets-firm-as-chinese-new-year-front-loading-reshapes-early-year-demand/?utm_source=openai)) - **Japan–US (ocean):** - As part of the wider Transpacific, Japan‑origin FEUs see: - **Low demand but higher costs** due to fuel and risk premiums, with carriers deploying **blank sailings (100+ in Feb 2026)** to prop up spot levels.([jmrodgers.com](https://www.jmrodgers.com/wp-content/uploads/2026/02/JMR-Freight-Market-Update-February-2026-v1.0.pdf?utm_source=openai)) - Net effect: **spot rates from Japan to US West Coast up vs early‑2025 lows**, but still historically moderate (around low‑ to mid‑USD 2,000s/FEU range as of April).([reddit.com](https://www.reddit.com/r/zim/comments/1sf3znx/freightos_weekly_update_april_7_2026_excerpts/?utm_source=openai)) - **Japan–Europe (ocean):** - Asia–Europe routes face **higher rates (30% YoY increase)** amid conflict‑related diversions and fuel surcharges; Japanese exports on Asia‑North Europe loops share these dynamics.([reddit.com](https://www.reddit.com/r/zim/comments/1sf3znx/freightos_weekly_update_april_7_2026_excerpts/?utm_source=openai)) **Key takeaways for a shipper/exporter using Japan as an origin hub in 2026** - Expect **tighter air‑cargo capacity ex‑Japan vs broader Asia**, but a **globally oversupplied air market overall**, keeping long‑term rate trajectories flat to down but with seasonal spikes.([iata.org](https://www.iata.org/en/iata-repository/publications/economic-reports/quarterly-air-transport-chartbook-q1-2026/?utm_source=openai)) - On the ocean side, **carriers are actively manipulating effective capacity (blank sailings, slow steaming)** on Transpacific and Asia–Europe, so: - **Japan–US and Japan–Europe spot rates in 2026 are higher than early‑2025 troughs**, but still far below pandemic‑era peaks; - Schedule reliability and space availability will be more volatile than the underlying demand would suggest.([jmrodgers.com](https://www.jmrodgers.com/wp-content/uploads/2026/02/JMR-Freight-Market-Update-February-2026-v1.0.pdf?utm_source=openai)) **Sources – Market Events** ([iata.org](https://www.iata.org/en/iata-repository/publications/economic-reports/quarterly-air-transport-chartbook-q1-2026/?utm_source=openai)) === 2. [DEMAND SIGNALS] Japan healthcare & pharmaceutical exports 2026 – cold chain, clinical trials, medtech exports === **Macro role of healthcare/medtech in Japan’s export basket** - World’s Top Exports’ 2025 profile shows **“optical, technical, and medical apparatus” at USD 36.6 bn, accounting for 5% of Japan’s total exports (2024–25)**, underscoring Japan’s role as a high‑value medtech exporter.([worldstopexports.com](https://www.worldstopexports.com/japans-top-10-exports/?utm_source=openai)) - A late‑2025 JETRO market report on Japan’s medical device industry estimates **Japan’s share at 5.7% of the global device market (USD 28.9 bn in 2024)** and notes that Japan heavily imports certain classes but is also a significant exporter of diagnostic imaging, in vitro diagnostics, and high‑end equipment.([jetro.go.jp](https://www.jetro.go.jp/ext_images/en/invest/img/attractive_sectors/06.pdf?utm_source=openai)) **Medical device / medtech exports – volume and growth indicators** - World Bank/UN Comtrade data for HS 901890 (instruments and appliances used in medical or veterinary sciences) show that **Japan’s exports in this HS line in 2024** include large flows to China, Korea, US, and EU, running into the **multi‑billion‑dollar equivalent in FOB values**; individual partner lines show exports to China of **95.53 million units valued at about USD 258 million** (single HS/partner combination). This is one of many HS‑based medtech lines where Japan has a strong surplus.([wits.worldbank.org](https://wits.worldbank.org/trade/comtrade/en/country/JPN/year/2024/tradeflow/Exports/partner/ALL/product/901890?utm_source=openai)) - Euromonitor’s 2024–2029 forecast for **medical and surgical equipment (Japan, ISIC 3311)** puts the domestic market at **USD 24.7 bn in 2024**, with positive production and export growth expected through 2029, driven by ageing demographics and export demand from Asia, North America, and Europe.([euromonitor.com](https://www.euromonitor.com/medical-and-surgical-equipment-in-japan-isic-3311/report?utm_source=openai)) - The US Commercial Service 2024–25 guide on Japan’s medical devices market notes that Japan is among the **top three export destinations for EU medtech and US exporters**, implying strong bidirectional trade volumes.([trade.gov](https://www.trade.gov/country-commercial-guides/japan-medical-devices?utm_source=openai)) **Pharmaceuticals and biologics – export growth & cold‑chain intensity** - Cushman & Wakefield’s analysis of **Japan’s pharmaceutical cold chain** (though older, still structurally relevant) shows: - Japan’s pharmaceutical **exports grew 13% YoY in 2019 to JPY 733 bn**, while imports grew 4.4% to JPY 3,092 bn. - The report highlights rapid expansion in **biopharmaceuticals and regenerative medicine**, which are **highly temperature‑sensitive and cold‑chain dependent**.([cushmanwakefield.com](https://www.cushmanwakefield.com/en/japan/insights/pharmaceutical-cold-chain?utm_source=openai)) - Ministry of Economy, Trade and Industry (METI) and MHLW’s “Vision for the Medical Device Industry” and related statistics describe **rapid growth in pharmaceuticals, biologics, and regenerative medicine** and point to Japan’s strategy to become a **regional hub for advanced therapies**, which structurally implies: - More **clinical trial materials**, cell and gene therapies, and biologics moving under **2–8°C and deep‑frozen conditions** across borders (high‑value air freight from/to US and Europe).([meti.go.jp](https://www.meti.go.jp/policy/mono_info_service/healthcare/iryou/downloadfiles/pdf/iryoukikisangyouvision2024/Vision_for_the_Medical_Device_Industry_2024.pdf?utm_source=openai)) **Demand signals: clinical trials and R&D‑linked traffic** - Japan remains a major destination for **global clinical trials**, particularly in oncology, cardiovascular, and regenerative medicine, as highlighted by METI and MHLW strategies (PMD Act reform, medical innovation policies). These emphasise: - **Shorter development timelines**, more **global multi‑centre trials**, and harmonisation with US/EU regulatory pathways. - This typically raises the volume of **time‑ and temperature‑sensitive investigational product shipments** between Japan, US, and Europe.([meti.go.jp](https://www.meti.go.jp/policy/mono_info_service/healthcare/iryou/downloadfiles/pdf/iryoukikisangyouvision2024/Vision_for_the_Medical_Device_Industry_2024.pdf?utm_source=openai)) - The PMD Act amendment process (final report in January 2025) emphasises post‑marketing surveillance, digital trial data, and flexibility for innovative modalities, which indirectly supports growth in **clinical supply chains and related cold chain movements** in 2025–26. **Cold‑chain logistics and healthcare exports – 2026 outlook** - While there is limited 2026‑specific numeric data for Japan’s cold‑chain export volumes, structurally: - Continued **13%‑type growth rates in pharma exports** (2019 benchmark) and expansion in biologics suggest **high‑single‑digit to low‑double‑digit CAGR in cold‑chain volumes** through mid‑2020s (inference from historic trend and strategic documents).([cushmanwakefield.com](https://www.cushmanwakefield.com/en/japan/insights/pharmaceutical-cold-chain?utm_source=openai)) - Airfreight remains the dominant mode for **high‑value biologics and clinical trial materials** on Japan–US and Japan–Europe lanes; with belly capacity tightening out of Japan in 2026 (IATA), **cold‑chain shippers will face competition for lift and likely premium pricing** on high‑priority sectors.([iata.org](https://www.iata.org/en/iata-repository/publications/economic-reports/quarterly-air-transport-chartbook-q1-2026/?utm_source=openai)) **Key 2026 demand signals for a logistics/market strategy** - **Growing medtech exports:** Japan’s role as a USD ~36–40 bn exporter of high‑tech medical/optical apparatus (5% of exports, and second‑largest med device market regionally) points to sustained outbound volumes to US and EU, requiring reliable air and ocean services with high value‑density.([worldstopexports.com](https://www.worldstopexports.com/japans-top-10-exports/?utm_source=openai)) - **Biopharma & advanced therapies:** Government policy and market data signal **expansion of biologics and regenerative medicine**, which are heavily **cold‑chain dependent**, especially for exports of APIs, finished biopharma, and clinical materials.([cushmanwakefield.com](https://www.cushmanwakefield.com/en/japan/insights/pharmaceutical-cold-chain?utm_source=openai)) - **Clinical trial flows:** Regulatory reforms to PMD Act and promotion of global trials indicate **rising cross‑border flows of investigational products, lab samples, and specialised devices** – favouring temperature‑controlled air freight and specialised logistics partners.([meti.go.jp](https://www.meti.go.jp/policy/mono_info_service/healthcare/iryou/downloadfiles/pdf/iryoukikisangyouvision2024/Vision_for_the_Medical_Device_Industry_2024.pdf?utm_source=openai)) **Sources – Demand Signals** ([worldstopexports.com](https://www.worldstopexports.com/japans-top-10-exports/?utm_source=openai)) === 3. [PROBLEM FRAMING] Japan customs & regulatory supply‑chain pain‑points (documentation, cold‑chain, FTAs) – 2026 === **General documentation and customs complexity** - While not Japan‑specific, a May 2026 practitioners’ discussion on export documentation notes that a **typical export shipment generates 8–12 documents** (shipping bill, commercial invoice, packing list, certificate of origin, B/L or AWB, plus commodity‑specific certificates), and that **2–4 hours per shipment** are often spent preparing documents for mid‑complexity consignments. Small errors in quantity, port codes, or HS codes frequently cause **customs delays and extra back‑and‑forth with customs brokers and authorities**.([reddit.com](https://www.reddit.com/r/exportersindia/comments/1t7frgk/how_are_you_handling_export_documentation_in_2026/?utm_source=openai)) - Applied to Japan, this aligns with trade‑promotion and industry guidance noting that: - **Japan Customs places strong emphasis on accurate HS classification, customs valuation, and complete commercial documentation**, particularly for regulated products like pharma/medtech; - Exporters often need **localized documentation formats and Japanese translations** for certain certificates and product information (e.g., medical device labelling) – increasing administrative burden.([trade.gov](https://www.trade.gov/country-commercial-guides/japan-medical-devices?utm_source=openai)) **Regulatory pain points – medical devices and pharmaceuticals** - The EU‑Japan Centre’s 2025 “How to Export to Japan (Medical Devices)” quick guide highlights several persistent exporter pain points: - Complex **pre‑marketing approval processes** under the PMD Act and the need for **Marketing Authorization Holder (MAH)** or **Designated MAH**, which foreign manufacturers must secure via local partners. - **Language and documentation requirements** (Japanese dossiers, labelling, IFUs), adding both time and compliance risk. - Differences in **technical standards and classification** vs US/EU that can create delays and additional testing/documentation.([eu-japan.eu](https://www.eu-japan.eu/publications/report-how-to-export-to-japan-medical-devices-quick-guide-2025?utm_source=openai)) - The PMD Act amendment timeline (final report Jan 2025) identifies four key themes: - Better risk management, digitalisation, post‑marketing safety, and promotion of innovation, but stakeholders note that **transition periods and new compliance expectations** can temporarily increase regulatory uncertainty for importers/exporters of drugs and devices in 2025–26.([meti.go.jp](https://www.meti.go.jp/policy/mono_info_service/healthcare/iryou/downloadfiles/pdf/iryoukikisangyouvision2024/Vision_for_the_Medical_Device_Industry_2024.pdf?utm_source=openai)) **Cold‑chain specific pain points** - Cushman & Wakefield’s review of Japan’s pharmaceutical cold chain underscores several structural challenges: - Need for **strict temperature control and traceability** across air, ocean, and domestic legs; - Requirement to comply with **Good Distribution Practice (GDP)** and **MHLW/METI guidelines** on handling biologics and temperature‑sensitive pharmaceuticals; - Limited availability (relative to demand growth) of **GDP‑compliant storage near major airports and ports**, leading to bottlenecks and cost premiums for pharma exporters/importers.([cushmanwakefield.com](https://www.cushmanwakefield.com/en/japan/insights/pharmaceutical-cold-chain?utm_source=openai)) - As Japan expands regenerative medicine and biologics, these constraints become more acute: exporters report **tight capacity for 2–8°C and ‑20°C/‑80°C lanes**, and heightened risk of shipment rejections or write‑offs if temperature excursions occur, given stringent Japanese quality requirements. (This is an inference based on the growth of high‑value biologics and existing infrastructure commentary.)([cushmanwakefield.com](https://www.cushmanwakefield.com/en/japan/insights/pharmaceutical-cold-chain?utm_source=openai)) **FTAs and rules‑of‑origin (RoO) compliance** - Japan is party to major FTAs that affect medtech/pharma trade, including: - **EU–Japan Economic Partnership Agreement (EPA)** - **CPTPP** and **RCEP**, plus numerous bilateral EPAs. These open preferential tariff access but add complexity in **rules‑of‑origin documentation**, cumulation rules, and HS‑based product specific rules. Trade advisory sources flag: - Errors in **origin certification and HS classification** as common causes of **denied preferential treatment** or post‑clearance audits.([eu-japan.eu](https://www.eu-japan.eu/publications/report-how-to-export-to-japan-medical-devices-quick-guide-2025?utm_source=openai)) - For EU medtech exporters using the EU–Japan EPA, MedTech Europe and EU‑Japan Centre note the need for: - **Precise origin documentation**, supplier declarations, and product‑specific RoO calculations; - Monitoring of **tariff phase‑out schedules** and product reclassification events that can change eligibility; all of which raise the compliance burden for exporters/importers who want to maximise FTA benefits.([eu-japan.eu](https://www.eu-japan.eu/publications/report-how-to-export-to-japan-medical-devices-quick-guide-2025?utm_source=openai)) **Operational and supply‑chain pain‑points into/out of Japan (2024–26)** - Trade and logistics advisories consistently flag for Japan: - **Port and airport congestion spikes** in peak seasons; - **Carrier schedule changes and blank sailings** on key ocean trades (e.g., Transpacific alliances serving Japan), increasing lead‑time variability and documentation re‑work (e.g., revising B/Ls, manifests, and customs entries when sailings are cancelled or rolled).([jmrodgers.com](https://www.jmrodgers.com/wp-content/uploads/2026/02/JMR-Freight-Market-Update-February-2026-v1.0.pdf?utm_source=openai)) - Tight **air‑cargo capacity** from Japan in certain periods (IATA’s projected capacity contraction in Q2‑2026), which can force shippers to **rebook on alternative routings** via other Asian hubs, adding customs transit complexity and risk of temperature excursions for cold‑chain goods.([iata.org](https://www.iata.org/en/iata-repository/publications/economic-reports/quarterly-air-transport-chartbook-q1-2026/?utm_source=openai)) **Summarised 2026 problem framing for Japan exporters/importers (with focus on healthcare/cold chain)** - **Documentation & customs:** - High document count (8–12 documents per shipment) and **2–4 hours preparation time per shipment**, with error‑sensitive customs processes; for Japan, add strict documentation quality and occasional need for Japanese language.([reddit.com](https://www.reddit.com/r/exportersindia/comments/1t7frgk/how_are_you_handling_export_documentation_in_2026/?utm_source=openai)) - **Regulatory:** - Evolving PMD Act and high regulatory bar for pharmaceuticals/medtech create **approval, labelling, and post‑marketing surveillance obligations** that can delay launches and complicate cross‑border flows.([jetro.go.jp](https://www.jetro.go.jp/ext_images/en/invest/img/attractive_sectors/06.pdf?utm_source=openai)) - **Cold‑chain:** - Infrastructure and GDP compliance requirements are tightening; there is **growing demand for temperature‑controlled storage and transport around Japanese gateways**, with risk of bottlenecks and costly failures if temperature excursions occur.([cushmanwakefield.com](https://www.cushmanwakefield.com/en/japan/insights/pharmaceutical-cold-chain?utm_source=openai)) - **FTAs & RoO:** - Multiple overlapping FTAs create opportunity but also **RoO and certification complexity**, with common pain points around HS codes, supplier declarations, and origin proofs.([eu-japan.eu](https://www.eu-japan.eu/publications/report-how-to-export-to-japan-medical-devices-quick-guide-2025?utm_source=openai)) - **Capacity and network volatility:** - Blank sailings and air‑capacity contractions out of Japan introduce **uncertainty in lead times and capacity**, requiring robust planning, buffer stock, and possibly multimodal/alternate‑hub strategies for sensitive healthcare exports.([jmrodgers.com](https://www.jmrodgers.com/wp-content/uploads/2026/02/JMR-Freight-Market-Update-February-2026-v1.0.pdf?utm_source=openai)) **Sources – Problem Framing** ([reddit.com](https://www.reddit.com/r/exportersindia/comments/1t7frgk/how_are_you_handling-export-documentation_in_2026/?utm_source=openai))